Figure 4.

Positive metabolic effects of the 11β-HSD1 inhibitor, compound C, appear to be “off target.” A, Body weight change in WT mice with compound C treatment. □, vehicle-treated WT; ■, 100 mg/kg/d compound C–treated WT. B, Body weight change in GKO mice with compound C treatment. ○, vehicle-treated GKO; ●, 100 mg/kg/d compound C–treated GKO. C, Percentage body weight change on day 25 of treatment. D, Cumulative food intake during the 25-day treatment. E, Fed leptin levels in terminal plasma taken on treatment day 25. F, Fasting glucose levels on treatment day 20. Data are expressed as means ± SEM; n = 5 to 7 mice per group. ***, P < .001 vs HFD-fed mice.